Advertisement

Pharmacy World & Science

, Volume 32, Issue 3, pp 386–393 | Cite as

Access to children’s medicines in the United Kingdom, Australia and New Zealand in 1998, 2002 and 2007

  • Rajan RagupathyEmail author
  • June Tordoff
  • Pauline Norris
  • David Reith
Research Article

Abstract

Objective To describe the listing of prescription entities (unique active agents only available on prescription) in standard reference texts that were licensed for children (0–18 years), in dosage forms suitable for children, and subsidised (Government funded) for children. Setting The United Kingdom, Australia and New Zealand in 1998, 2002 and 2007. Method A review of data from 1998, 2002, and 2007 using standard prescribing and subsidy reference sources in each country. The study examined all prescription entities, orally available entities, and entities newly licensed for children 2002–2007. Main outcome measure Changes in the number of prescription entities that were licensed, suitably formulated and subsidised for children over the period. Results The United Kingdom had the highest number of prescription entities (1149 in 1998; 1049 in 2007), entities licensed for children (677; 564), entities suitably formulated for children (791; 676), and entities licensed for children and subsidised (677; 562) over the period. However, the numbers and proportions of entities licensed for children and suitably formulated for children decreased over the period of the study. New Zealand and Australia had lower numbers throughout the period, but the number of entities licensed for children (New Zealand 319–450, Australia 288–466) and entities licensed for children and subsidised (New Zealand 245–288, Australia 155–254) increased over the period. Conclusion Over the period of the study, there was a decrease in listed prescription entities that were licensed for children in the United Kingdom, but an increase in Australia and New Zealand. There were considerably fewer entities licensed, suitably formulated and subsidised for children than for adults at all three time points and in all three countries. This reinforces the need for the current initiatives to improve access to medicines for children.

Keywords

Australia Dosage forms Drug therapy Healthcare disparities New Zealand Paediatrics United Kingdom 

Notes

Acknowledgements

Innova Software provided complimentary copies of the Australia Prescription Products CD-ROM for use in this study. Editorial staff at Datapharm Communications were very prompt and helpful in answering questions about the electronic Medicines Compendium.

Funding

None.

Conflicts of interest statement

None.

References

  1. 1.
    Organisation for Economic Co-operation and Development. Members and partners. http://www.oecd.org/pages/0,3417,en_36734052_36761800_1_1_1_1_1,00.html. Accessed 21 Nov 2009.
  2. 2.
    Central Intelligence Agency. The World Factbook. https://www.cia.gov/library/publications/the-world-factbook/geos/uk.html. Accessed 21 Nov 2009.
  3. 3.
    New Zealand Medicines and Medical Devices Safety Authority (Medsafe). About Medsafe. http://www.medsafe.govt.nz/other/about.asp. Accessed 21 Nov 2009.
  4. 4.
    Australian Government Department of Health and Ageing Therapeutic Goods Administration. Regulation of therapeutic goods in Australia. http://www.tga.gov.au/docs/html/tga/tgaginfo.htm. Accessed 21 Nov 2009.
  5. 5.
    The Medicines and Healthcare Products Regulatory Agency. Medicines and medical devices regulation: what you need to know. http://www.mhra.gov.uk/home/groups/comms-ic/documents/websiteresources/con2031677.pdf. Accessed 21 Nov 2009.
  6. 6.
    The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Welcome to the Official Website for ICH. http://www.ich.org/cache/compo/276-254-1.html. Accessed 21 Nov 2009.
  7. 7.
    Chui J, Tordoff J, Kennedy J, Reith D. Trends in accessibility to medicines for children in New Zealand: 1998–2002. Br J Clin Pharmacol. 2004;57(3):322–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Balakrishnan K, Tordoff J, Norris P, Reith D. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998–2002. Br J Clin Pharmacol. 2007;63(1):85–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Chui J, Tordoff J, Reith D. Changes in availability of paediatric medicines in Australia between 1998 and 2002. Br J Clin Pharmacol. 2005;59(6):736–42.CrossRefPubMedGoogle Scholar
  10. 10.
    Turner S, Gill A, Nunn T, Hewitt B, Choonara I. Use of “off label” and unlicensed drugs in paediatric intensive care unit. Lancet. 1996;347(9000):549–50.CrossRefPubMedGoogle Scholar
  11. 11.
    McLay JS, Tanaka M, Ekins-Daukes S, Helms PJ. A prospective questionnaire assessment of attitudes and experiences of off label prescribing among hospital based paediatricians. Arch Dis Child. 2006;91(7):584–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Horen B, Montastruc J, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002;54(6):665–70.CrossRefPubMedGoogle Scholar
  13. 13.
    Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr. 1999;88(9):965–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Ufer M, Kimland E, Bergman U. Adverse drug reactions and off-label prescribing for paediatric outpatients: a one year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Saf. 2004;13(3):147–52.CrossRefPubMedGoogle Scholar
  15. 15.
    Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004;27(13):1059–67.CrossRefPubMedGoogle Scholar
  16. 16.
    Cuzzolin L, Zaccaron A, Fanos V. Unlicensed and off-label uses of drugs in paediatrics: a review of the literature. Fundam Clin Pharmacol. 2003;17(1):125–31.CrossRefPubMedGoogle Scholar
  17. 17.
    Pandolfini C, Bonati M. A literature review on off-label drug use in children. Eur J Pediatr. 2005;164(9):552–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Schirm E, Tobi H, De Vries TW, Choonara I, De Jong-van den Berg LT. Lack of appropriate formulations of medicines for children in the community. Acta Paediatr. 2003;92(12):1486–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Nunn T, Williams J. Formulation of medicines for children. Br J Clin Pharmacol. 2005;59(6):674–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Datapharm Communications Ltd. electronic Medicines Compendium (eMC). http://emc.medicines.org.uk/. Accessed 21 Nov 2009.
  21. 21.
    United Kingdom National Health Service (NHS) Business Services Authority. NHS Electronic Drug Tariff. http://www.ppa.org.uk/edt/December_2007/mindex.htm. Accessed 21 Nov 2009.
  22. 22.
    Innova Software. Electronic Australian Prescription Products Guide (April 2007). [CD-ROM] 2007.Google Scholar
  23. 23.
    Australian Government Department of Health and Ageing. PBS for health professionals. http://www.pbs.gov.au/html/healthpro/home. Accessed 21 Nov 2009.
  24. 24.
    Donohoo E, editor. MIMS New Ethicals Jan–July 2007. Auckland: CMP Medica; 2007. ISSN: 1176-5844.Google Scholar
  25. 25.
    New Zealand Medicines and Medical Devices Safety Authority (Medsafe). Information for health professionals: data sheets. http://www.medsafe.govt.nz/profs/Datasheet/dsform.asp. Accessed 21 Nov 2009.
  26. 26.
    Pharmaceutical Management Agency of New Zealand (PHARMAC). Interactive pharmaceutical schedule. http://www.pharmac.govt.nz/Schedule. Accessed 21 Nov 2009.
  27. 27.
    STATA Version 9.0. College Station, TX, USA: Stata.Google Scholar
  28. 28.
    World Health Organization. Who collaborating centre for drugs statistics methodology. http://www.whocc.no/atcddd/. Accessed 21 Nov 2009.
  29. 29.
    Royal Pharmaceutical Society of Great Britain Information Centre. Mergers and takeovers within the pharmaceutical industry. http://www.rpsgb.org/pdfs/mergers.pdf. Accessed 21 Nov 2009.
  30. 30.
    Young L, Lawes F, Tordoff J, Norris P, Reith D. Access to prescribing information for paediatric medicines in the USA: post-modernization. Br J Clin Pharmacol. 2009;67(3):341–6.CrossRefPubMedGoogle Scholar
  31. 31.
    United States Food and Drug Administration. Regulatory information: best pharmaceuticals for children act. http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ucm148011.htm. Accessed 21 Nov 2009.
  32. 32.
    United States Food and Drug Administration. Pediatric drug development: FDA amendments act of 2007 (FDAAA). http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM049870.pdf. Accessed 21 Nov 2009.
  33. 33.
    European Medicines Agency. Medicines for children: the EU paediatric regulation. http://www.emea.europa.eu/htms/human/paediatrics/regulation.htm. Accessed 21 Nov 2009.
  34. 34.
    Permanand G, Mossialos E, McKee M. The EU’s new paediatric medicines legislation: serving children’s needs? Arch Dis Child. 2007;92(9):808–11.CrossRefPubMedGoogle Scholar
  35. 35.
    Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs-evidence from 25 major markets in the 1990s. Health Econ. 2005;14(3):269–92.CrossRefPubMedGoogle Scholar
  36. 36.
    Australian Government Department of Health and Ageing. Pharmaceutical benefits schedule. http://www.pbs.gov.au/html/home. Accessed 21 Nov 2009.
  37. 37.
    Paediatric Formulary Committee. BNF for children. London: BMJ Publication Group, RPS Publishing, RCPCH Publications; 2008. ISBN-10: 0853697809.Google Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Rajan Ragupathy
    • 1
    Email author
  • June Tordoff
    • 1
  • Pauline Norris
    • 1
  • David Reith
    • 2
  1. 1.School of PharmacyUniversity of OtagoDunedinNew Zealand
  2. 2.Dunedin School of MedicineUniversity of OtagoDunedinNew Zealand

Personalised recommendations